Pharmaceutical Companies

Under the agreement, QuantumCell will obtain global rights to AlzeCure’s NeuroRestore platform, including its lead drug candidate, ACD856.

The agreement brings together Lilly’s expertise in developing innovative medicines with Abu Dhabi’s advanced healthcare infrastructure, population-scale health data, and genomics capabilities.

The announcement came during Moderna’s Science Day, where the biotechnology company outlined plans to broaden its pipeline across oncology, rare diseases, and immune-mediated disorders.

Through the HELM Cluster, the emirate has brought together research institutions, advanced healthcare infrastructure, genomics programs, manufacturing capabilities, and distribution networks within a single ecosystem.

Antares will lead the research phase and apply its proprietary drug-discovery platform to a limited number of oncology targets before Novartis decides whether to exercise licensing options for individual programmes.

The move marks an important step toward evaluating the technology for Good Manufacturing Practice (GMP)-compliant manufacturing while improving the efficiency of producing next-generation medicines.

The acquisition is expected to strengthen Merck’s position in the rapidly growing life sciences sector, particularly in areas such as cell and gene therapy, precision diagnostics, multi-omics research, and biopharmaceutical manufacturing.

The proposed centre will operate within Abu Dhabi’s Health, Endurance, Longevity, and Medicine (HELM) Cluster, a strategic life sciences platform that integrates research, healthcare delivery, investment, commercialization, and biomanufacturing.

The acquisition ranks among AbbVie’s largest transactions in recent years and reflects the company’s strategy to expand its next-generation immunology medicines as competition intensifies across the sector.

Under the agreement, Biogen will integrate RayThera’s portfolio of anti-inflammatory and immune-modulating candidates into its broader research and development engine.